Navigation Links
Ocular Therapeutix Commences Pilot Phase II Travoprost Punctum Plug Study for the Treatment of Glaucoma
Date:8/20/2012

BEDFORD, Mass., Aug. 20, 2012 /PRNewswire/ -- Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma. Ocular Therapeutix's travoprost punctum plugs are inserted into the proximal nasolacrimal canal, and release drug to the ocular surface over the two-month treatment period.

The initial travoprost punctum plug feasibility study, conducted at the Singapore National Eye Center and the National University Hospital in Singapore, examined efficacy of the technology over a 1-month duration. "Having demonstrated proof of concept in our feasibility study, we have extended the length of drug delivery to two months for the pilot Phase II trial," stated Amar Sawhney, Ph.D., President and CEO of Ocular Therapeutix, Inc.  "Extending treatment duration for the disease is a key milestone for our company's path to commercialization."

The pilot Phase II study will enroll twenty patients (up to 40 eyes) at the Umhlanga Hospital Medical Centre and Netcare Alberlito Hospital in South Africa.  Patients with documented ocular hypertension or open-angle glaucoma, the most common form of the disease, will be evaluated for reduction of intraocular pressure from baseline and retention of the plug through two months.  Elevated intraocular pressure is the most important risk factor for glaucoma.

Glaucoma is a chronic disease which must be monitored and treated for life, impacting more than 2 million Americans, and represents a $5 billion market worldwide.  The current mode of treatment for the disease is topical prescription drops which must be taken daily and at regular intervals to prevent progression of the disease.  However, topical prescriptions are plagued with issues of non-compliance, which can lead to costly and invasive surgeries, vision impairment, and even blindness.  It has been reported that up to 60% of patients do not administer ophthalmic drops as directed, even though patients' perception is that they are compliant with 97% of their dosing.1

"Travoprost Punctum Plugs may help to overcome issues of daily self-administration of medication leading to potential patient non-compliance," stated Pierre Wassermann, Principal Investigator at the Umhlanga Hospital Medical Centre in South Africa.  "Additionally, maintaining continuous drug presence via sustained delivery may be an improvement over fluctuating drug levels resulting from daily topical therapy."

About Ocular Therapeutix's Travoprost Punctum Plugs:

Ocular Therapeutix's travoprost punctum plugs use the company's proprietary polyethylene glycol hydrogel technology to release travoprost in a sustained fashion over a specified period of time.  At the end of the treatment period, the plug begins to absorb, and exit the nasolacrimal system without need for removal by the physician. The plugs contains a visualization agent for retention monitoring throughout the treatment period. 

About Ocular Therapeutix, Inc.:

Founded in November 2006, Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. Ocular Therapeutix is using its hydrogel technology for development of a variety of ophthalmic applications including hydrogel sealants for ocular surface protection, drug-eluting punctal plugs for treatment of various anterior segment diseases, and with therapeutic agents for back-of-the-eye diseases.

1Goldberg I. Compliance with Medical Management in Glaucoma. Asian J of Ophthalmol 2000;2(4):3-6.


'/>"/>
SOURCE Ocular Therapeutix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inaugural National Mobility Awareness Month Commences in May Saluting the More than 18 Million with Disabilities
2. Bausch + Lomb Commences Tender Offer of Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3 and U07190AA6)
3. American Pacific Corporation Commences Debt Refinancing
4. Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
5. Bluechiip Receives First Sales Order from ATCC after Completion of Successful Pilot Trial
6. In Pilot Study, a Peptide Controls Blood Sugar in People with Congenital Hyperinsulinism
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 2017 , ... The National Business Research Institute (NBRI) is ... Emergency Medical Technicians and welcomes this organization to the NBRI Circle of ... Ph.D. , CEO & Organizational Psychologist at NBRI. “This award is a result ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which ... nutrients from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... the body recognizes its raw form (unlike the synthetically made options that are on ...
(Date:4/26/2017)... Pa. (PRWEB) , ... April ... ... division, which provides an agile ecosystem and domain expertise for sponsors and ... configurable randomization and trial supply management (RTSM) software platform. Bioclinica AGILE ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 product ... for education and business. , Mirroring360 Pro enables educators, business professionals and individuals ...
(Date:4/25/2017)... ... 25, 2017 , ... A stressful work environment can hurt the physical and ... and performance in the workplace. The goal of Clearview Resolution Services has always been ... April, Clearview Resolution Services will be shutting down the office early on Fridays. The ...
Breaking Medicine News(10 mins):